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Background: Low-dose interleukin-2 (ld-IL-2) enhances regulatory T-cell (Treg) function in auto-inflamma-
tory conditions. Neuroinflammation being a pathogenic feature of amyotrophic lateral sclerosis (ALS), we
evaluated the pharmacodynamics and safety of ld-IL-2 in ALS subjects.
Methods: We performed a single centre, parallel three-arm, randomised, double-blind, placebo-controlled
study. Eligibility criteria included age < 75 years, disease duration < 5 years, riluzole treatment > 3 months,
and a slow vital capacity  70% of normal. Patients were randomised (1:1:1) to aldesleukin 2 MIU, 1 MIU, or
placebo once daily for 5 days every 4 weeks for 3 cycles. Primary outcome was change from baseline in Treg
percentage of CD4+ T cells (%Tregs) following a first cycle. Secondary laboratory outcomes included: %Treg
and Treg number following repeated cycles, and plasma CCL2 and neurofilament light chain protein (NFL)
concentrations as surrogate markers of efficacy. Safety outcomes included motor-function (ALSFRS-R), slow
vital capacity (SVC), and adverse event reports. This trial is registered with ClinicalTrials.gov, NCT02059759.
Findings: All randomised patients (12 per group), recruited from October 2015 to December 2015, were alive
at the end of follow-up and included in the intent-to-treat (ITT) analysis. No drug-related serious adverse
event was observed. Non-serious adverse events occurred more frequently with the 1 and 2 MIU IL-2 dosesKeywords:
Amyotrophic lateral sclerosis
Randomised clinical trial
Low dose interleukin-2
Neuro-inflammation
Biomarkers
Regulatory T cellsCentre, Guy's and St Thomas' NHS Foundation Trust and King's College London, London, UK.
ogy, AP-HP.Sorbonne Universite, Pitie-Salpe^triere Hospital, 47, Bd de l’Ho^pital, F-75013 Paris, France.
ensimon.psl@gmail.com (G. Bensimon).
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2 W. Camu et al. / EBioMedicine 00 (2020) 102844compared to placebo, including injection site reactions and flu-like symptoms. Primary outcome analysis
showed a significant increase (p < 0¢0001) in %Tregs in the 2 MIU and 1 MIU arms (mean [SD]: 2 MIU: +6¢2%
[2¢2]; 1 MIU: +3¢9% [1¢2]) as compared to placebo (mean [SD]: -0¢49% [1¢3]). Effect sizes (ES) were large in
treated groups: 2 MIU ES=3¢7 (IC95%: 2¢34¢9) and 1 MIU ES=3¢5 (IC95%: 2¢14¢6). Secondary outcomes
showed a significant increase in %Tregs following repeated cycles (p < 0¢0001) as compared to placebo, and a
dose-dependent decrease in plasma CCL2 (p = 0¢0049). There were no significant differences amongst the
three groups on plasma NFL levels.
Interpretation: Ld-IL-2 is well tolerated and immunologically effective in subjects with ALS. These results war-
rant further investigation into their eventual therapeutic impact on slowing ALS disease progression.
Funding: : The French Health Ministry (PHRC-I-14-056), EU H2020 (grant #633413), and the Association pour
la Recherche sur la SLA (ARSLA).
© 2020 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license.
(http://creativecommons.org/licenses/by-nc-nd/4.0/)1. Introduction
Amyotrophic Lateral Sclerosis (ALS) is a fatal neuromuscular
disorder characterised by progressive muscle wasting and weak-
ness. Since the introduction of riluzole two decades ago [1],
trials have failed to deliver more effective disease-modifying
remedies. Recent consensus guidelines for ALS trials emphasise
the importance of incorporating biomarkers of target engage-
ment and disease activity at an early stage of therapeutic
development [2].20 with the terms
l trials)”. We also
kin-2 OR IL-2)” AND
r neuron disease)” as
R motor neuron dis-
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R IL-2)” AND “(rand-
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ovides a sound evi-
IL-2 in ALS and other
peated 5-day cycles of low d
lled trial, EBioMedicine (202Microglial cell activation is evident in the pathology of ALS at all
disease stages [3] and in the transgenic SOD1 ALS mouse in which
expression of macrophage-typical cytokines precedes clinical symp-
toms [4]. Furthermore, biomarkers of neuro-inflammation are ele-
vated in patients with ALS and have been shown to correlate with
disease severity and predict disease progression [5,6].
Although evidence of a neuro-inflammatory contribution to ALS
pathogenesis is compelling [7], until now all therapeutic attempts to
modify the neuro-inflammatory response in the ALS clinical context
have failed [8]. However, most of these trials have targeted non-spe-
cific suppression of neuro-inflammation. Such approaches have a
high risk of harm for people with ALS, where toxicity may outweigh a
beneficial drug effect. In this context, reinforcing physiological tolero-
genic dominance within the neuroimmuno-inflammatory system
may provide a more effective approach to control cytopathic neuroin-
flammatory states compared to aggressive general immune suppres-
sion.
CD4+FOXP3+ regulatory T-cells (Tregs) physiologically regulate
immune responses, contributing to the induction and maintenance of
tolerance, thus preventing the onset of autoimmune and inflamma-
tory diseases [9]. Previous studies have shown that in ALS patients,
decreased levels of Tregs were correlated with increased disease
severity and were predictive of disease progression and survival, sug-
gesting that they may be a potential target for therapy [1012]. Tregs
are exclusively reliant on the cytokine Interleukin 2 (IL-2) for their
generation, activation and survival [13]. Low dose IL-2 (ld-IL-2)
administration induces the selective expansion of Tregs in mice and
humans [14,15]. Several clinical trials exploring the therapeutic
potential of ld-IL-2 in auto-immune and inflammatory conditions
have now been reported, showing the feasibility and clinical safety of
this approach [16]. Building upon our experience with ld-IL-2 in
type-1 diabetes [17], we therefore examined the safety and pharma-
codynamic effects of ld-IL-2 in ALS through a phase-2a, randomised,
double-blind, placebo-controlled trial. Our primary objective was to
verify within a small pilot study, whether immune and inflammatory
parameters of ALS patients could be modified with low dose IL-2
therapy towards an improved tolerogenic state, with an acceptable
safety profile.2. Methods
2.1. Study design and participants
This three-arm, randomised (1:1:1), double-blind, single-centre
study of 2 doses of ld-IL-2 in parallel versus placebo included patients
at the Montpellier Amyotrophic Lateral Sclerosis Reference Centre in
France. The study protocol was submitted by the Sponsor (Centre
Hospitalier Universitaire de Nı^mes) and approved by an independent
ethics committee (Le Comite de Protection des Personnes Sud
Mediterranee III; reference number: 2014.09.01-ter), declared on clin-
icaltrials.gov (NCT02059759) and was designed for adults less thanose aldesleukin in amyotrophic lateral sclerosis (IMODALS): A phase
0), https://doi.org/10.1016/j.ebiom.2020.102844
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nite ALS as defined by El Escorial Revised ALS diagnostic criteria [18].
The main inclusion criteria consisted of disease duration of less than
5 years, stable on riluzole treatment for over three months, and a vital
capacity  70% of normal. Patients with severe cardiac or pulmonary
disease, cancer, other life-threatening diseases, respiratory or feeding
assistance, clinical signs of infection, positive serology (IGM) for
recent infections (cytomegalovirus, Epstein-Barr virus), or human
immunodeficiency virus, auto-immune disorders (except asymptom-
atic Hashimoto thyroiditis), any clinically significant laboratory
abnormality (excepting cholesterol, triglyceride and glucose), or
other diseases precluding functional assessments were excluded, as
were those who had received a vaccination in the 8 weeks preceding
the first experimental dosing. All patients provided signed informed
consent before entering the study.
2.2. Randomisation and masking
Allocation was performed and blinding assured via a web-based
inclusion and randomisation (with blocking) application. A statisti-
cian otherwise not involved in the study prepared randomisation
lists. The size of blocks (3) remained undisclosed to all participants
until unblinding. Clinical treatment unit (CTU) preparation and label-
ling were performed by a pharmacist at the Clinical Trial Pharmacy
Unit of the University Hospitals of Montpellier, France, who was the
only unblinded trial researcher. All laboratory assays were
completely blinded. Samples were only identified by barcodes with
the correspondence to randomisation number, time in the study
(number of sampling time points=7), or treatment group (placebo, 1
MIU IL-2, 2 MIU IL-2), unknown to the laboratory producing the data.
Prior to unblinding, accuracy of sample labelling was tested via geno-
typing of 20 common single nucleotide polymorphisms (LGC Geno-
mics Division, Hoddenson, UK) allowing us to correct one mismatch
on two samples over 251 samples collected.
2.3. Procedures
Upon inclusion by an investigating physician, baseline assess-
ments were performed and included: routine blood haematology,
biochemistry, and thyroid function tests, slow vital capacity, ALS
Functional Rating Scale Revised (ALSFRS-R), chest x-ray, and electro-
cardiogram (Fig. 1). Following randomisation ( 2 weeks before first
administration on day 1), patients started a 5-day cycle of once-daily
sub-cutaneous injections. 5-day cycles were repeated twice, on
weeks 5 and 9, for a total of 3 cycles of treatment per patient (Fig. 1).
After the last treatment cycle, all patients were followed up for safety
monitoring for a further 3 months.
Proleukin (aldesleukin) at 22 MIU vials was purchased from
Novartis-Pharma France. Clinical trial unit pharmaceutical prepara-
tion consisted of visually identical 1 ml polypropylene syringes con-
taining 0¢5 ml of either placebo (glucose for injection preparation D
5% solution), or 1 MIU or 2 MIU of IL-2, according to randomisation.
Assessments performed during the 6-month study period are
indicated in Fig. 1. Vital signs, concomitant medications and adverse
events were assessed at each visit. Slow vital capacity was assessed
according to current recommendations (https://www.encals.eu/out
come-measures).
2.4. Clinical immunophenotyping
Clinical flow cytometry was performed by the Department for Cell
and Tissue Engineering of the Montpellier University Hospital,
France, within 2 h of phlebotomy. Peripheral blood was drawn into
EDTA tubes and stained with two panels of monoclonal antibodies to
identify CD3+, CD4+, CD8+ and regulatory T cells (Tregs; CD4+ CD25+
CD127low/- FoxP3+), NK cells, B lymphocytes and monocytes. APlease cite this article as: W. Camu et al., Repeated 5-day cycles of low d
2a randomised, double-blind, placebo-controlled trial, EBioMedicine (202representative gating scheme is shown in supplementary Fig. 1. B
cells, NK cells and CD3+ T cells are expressed as percentages of total
lymphocytes; CD4+ and CD8+ T cells are expressed as percentages of
CD3+ cells. Tregs are expressed as percentages of CD4+T cells. Effector
T cells (Teffs) are calculated as the difference between total CD4+ T
cells and Tregs and expressed as percentages of CD4+ T-cells. Mono-
cytes are expressed as percentages of CD45+ leukocytes.
2.5. Mechanistic immunophenotyping
At each study visit, 20 ml blood was collected into sodium heparin
tubes and peripheral blood mononuclear cells (PBMC) isolated and
cryopreserved as detailed in the supplementary methods. For analy-
sis of Treg function, cryopreserved PBMC were thawed and stained
with a cocktail of monoclonal antibodies (details in supplementary
methods). Suppression assays were then performed in V-bottom 96-
well plates by co-culturing 500 sorted CD4+CD25/low CD127+ Teffs in
the presence or absence of CD4+CD25high CD127low Tregs at various
ratios (Treg:Teff 0:1, 1:2 and 1:1) with 1 £ 103 CD19+B cells. Cells
were stimulated with PHA (4 mg/ml; Alere) and incubated at 37 °C,
5% CO2, for 6 days. Proliferation was assessed by the addition of 0¢5
mCi/well [3H] thymidine (PerkinElmer) for the final 20 h of co-cul-
ture. Conditions were run in 6 replicates, and proliferation readings
(counts per minute [CPM]) averaged. Any samples with averaged
proliferation less than 3000 CPM from the Teff wells alone were
excluded. The percentage suppression in each culture was calculated
using the following formula: percent suppression = 100  [(CPM in
the presence of Tregs  CPM in the absence of Tregs) £ 100]. All time
points from an individual were analysed concurrently.
2.6. Plasma chemokine determination
Plasma chemokine analysis was performed on 80 °C frozen
plasma samples at Humanitas Clinical and Research Centre, Milan
(Italy). CCL2 and CCL17 plasma levels were measured by Multiplex
bead assay (Luminex Human HS Cytokine Panel - R&D Systems), and
CCL18 by ELISA (Quantikine ELISA kit (DCL180B, R&D Systems).
2.7. Plasma neurofilament light chain protein determination
Plasma concentrations of the neurofilament light chain (NFL) pro-
tein were measured using an immunoassay with electrochemilumi-
nescent detection (Meso Scale Discovery) at Queen Mary University
of London, London (UK), as previously described in detail [19]. Plasma
NFL concentration was also measured using Single Molecule Array
(Simoa) technology, at the University of Gothenburg (Sweden), as
previously described in detail [20].
Full details of clinical and biochemical phenotyping methods are
provided in the supplementary material.
2.8. Outcomes
The primary pharmacodynamic outcome was the change in Tregs
as a percentage of CD4+ T-lymphocytes on day 8 measured by clinical
flow cytometry. Secondary pharmacodynamics were Treg number
and percentage at all time-points, including expression as incremen-
tal areas-under-the-curves (iAUC), and plasma levels of CCL2 and NFL
as markers of disease activity. Exploratory analyses included meas-
urements of the number and frequency of leucocyte populations by
flow cytometry as well as Treg cell functionality tests. Monocyte
polarisation in response to treatment was investigated through anal-
ysis of their chemokine production profile (CCL17 and CCL18). Safety
was assessed through a systematic check for predefined events
(injection site reactions, flu-like symptoms, fatigue, gastro-intestinal
signs, allergic reaction), abnormal vital signs, ECG results, chest radio-
graphs, laboratory tests, and records of all adverse events reportedose aldesleukin in amyotrophic lateral sclerosis (IMODALS): A phase
0), https://doi.org/10.1016/j.ebiom.2020.102844
Fig. 1. Trial profile. ALSFRS-R: Amyotrophic Lateral Sclerosis Functional Rating Score  Revised; BT: Routine blood tests (see supplementary methods for detail); Cyt: Fresh Blood
Cytometry (see supplementary methods for detail); SVC: slow vital capacity; PBMCs: Peripheral Blood Mononuclear Cells; Inj: sub-cutaneous injection; D: day; ECG: electrocardio-
gram; ITT: intention-to-treat. *Time frames corresponding to at-hospital visits.
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function (ALSFRS-R and slow vital capacity (SVC)) with time were
assessed throughout the study.
2.9. Sample size
Previous data [17] demonstrated that 6 patients per group
achieved 88% power to detect a 60% increase in Tregs at p a=0¢05
(Mann & Whitney test). Because impact on disease activity is also of
primary interest, we retained 12 patients per group to achieve 80%
power at p a(2-tailed)= 0¢05 for detecting a 40% decrease in plasma
NFL-MSD (Mann- Whitney U test) based on a previous ALS study [19].
Interim safety data were evaluated once by an Independent Data
and Safety Monitoring Board (DSMB) after the first 12 patients were
included and had completed a first cycle of treatment including day 8
assessments. The interim report remained undisclosed until the end
of the study.
2.10. Statistical analyses
Categorical variables are described as absolute and relative fre-
quencies. Quantitative variables are summarized by mean, standard
deviation, 95% confidence interval (95% CI), median and range. EffectPlease cite this article as: W. Camu et al., Repeated 5-day cycles of low d
2a randomised, double-blind, placebo-controlled trial, EBioMedicine (202size with 95% CI was calculated for the primary pharmacodynamics
outcome. Flow cytometry parameters were analysed as changes from
baseline at D8 (primary criteria) and D64, i.e. absolute differences
between each time point and baseline (D1). Overall immune cell
changes with time for the first (D1, D8, D29) and third cycles (D57,
D64, D85) were summarised as incremental time-normalised areas-
under-the-curves (iAUC, using the trapezoidal method), minus D1 or
D57 values respectively; iAUCt for trough values were calculated
using values measured at D1, D29, D57 and D85 minus D1. Eosinophil
counts were analysed in the same way as cytometry parameters.
ALSFRS-R measures were summarised by regression slopes from D1
to D85. For SVC and NFL-MSD, absolute differences between D85 and
baseline D1 were analysed. For CCL2, CCL17 and CCL18, baseline nor-
malised values at D64 were analysed. For statistical inferences with
regards to differences between the three study arms, we used a
Fisher-Hayter’s two-stage MCP testing strategy approach by first
using a Kruskal-Wallis H test (KW-H) checking for differences among
all groups, and only when significant at p < 0¢05, Mann-Whitney U
tests (MW-U) were used for pairwise comparisons of each active arm
to placebo, to pinpoint the detected differences without the need for
further adjusting the nominal p value threshold [21]. Dose-response
relationships on summary measures were analysed using Jonck-
heere-Terpstra J test (JT-J) assessing whether the change in outcomeose aldesleukin in amyotrophic lateral sclerosis (IMODALS): A phase
0), https://doi.org/10.1016/j.ebiom.2020.102844
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test). For within group comparisons of time-points we used a Wil-
coxon match-paired signed rank test (Wx-W test).
The full protocol is available upon request and access to material &
data are subjected to preliminary agreement with the Sponsor.
3. Results
Between September 21st and December 4th 2015, thirty-nine
patients were screened. Of these, 3 were excluded and 36 random-
ized (Fig. 1). After 12 inclusions and 1 cycle of treatment, the inde-
pendent DSMB found no safety concerns, and inclusions continued.
With only one exception (see Fig. 1), all randomised patients com-
pleted the 3 cycles of treatment over 3 months and the 3-month post
treatment follow-up. All 36 randomised patients were included in
the intention-to-treat and safety populations (Fig. 1). Of 252 maxi-
mum possible assessments for clinical and laboratory measurements
for primary/secondary outcomes in the trial, all but one were avail-
able for analysis (Fig. 1).
Patient characteristics and disease history are shown in Table 1
and Supplementary Tables 2 and 3. Though between-group baseline
differences were not statistically significant, the 2 MIU group had a
higher female-to-male ratio, and slightly more severe disease fea-
tures. Nonetheless, no clear imbalance that would influence the
results was identified between groups.
Clinical tolerance was satisfactory at both doses of IL-2. During the
entire follow-up (D1-D169), no drug-related serious adverse event
(SAE) occurred and most non-serious adverse events (NSAEs) were
transient and of mild to moderate grades. During the treatment
period (D1-D85), frequencies of patients presenting NSAEs during
cycles were higher in the IL-2 groups, n = 11 (92%) and n = 12 (100%)Table 1
Demographic and clinical baseline characteristics of study partici
Placebo (n = 12)
Age
Mean (SD) 56¢45 (9¢57)
Median (Range) 56¢20 (42¢2 to 69¢7
Sex (female) 3 (25%)
BMI
Mean (SD) 26¢80 (5¢6)
Median (Range) 25¢10 (22¢2 to 43¢4
Age at onset
Mean (SD) 54¢27 (9¢85)
Median (Range) 55¢30 (38¢1 to 68¢0
Disease duration (years)
Mean (SD) 2¢2 (1¢44)
Median (Range) 1¢75 (0¢5 to 5¢0)
Duration of riluzole treatment (months)
Mean (SD) 16¢58 (12¢49)
Median (Range) 12¢35 (4¢6 to 39¢8)
Diagnosis
Definite 5 (41¢7%)
Probable 5 (41¢7%)
Probable  laboratory supported 2 (16¢7%)
Familial form 0
Site of onset
Limb 11 (92%)
Bulbar 1 (8%)
Slow vital capacity (percentage predicted)
Mean (SD) 94¢4 (12¢4)
Median (Range) 96¢5 (77¢00 to 119
ALSFRS-R score
Mean (SD) 38¢8 (3¢4)
Median (Range) 38¢5 (34¢00 to 45¢0
NFL-MSD (pg/ml)
Mean (SD) 127.84 (89.90)
Median (Range) 116.6 (6.7 - 349.2)
Categorical data are presented as number (%). ALSFRS = Amyot
BMI = Body Mass Index. SD = standard deviation. NFL-MSD= neu
tion method (Meso Scale Discovery).
Please cite this article as: W. Camu et al., Repeated 5-day cycles of low d
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with placebo (Table 2). Local reactions at injection sites (erythema,
pain) were the most common NSAEs of comparable frequency in the
2 active treatment groups (all patients except one experienced injec-
tion site reactions) while only one patient reported such an event in
the placebo group. Flu-like symptoms (including myalgia, chills,
fever, arthralgia), which are characteristic of IL-2 treatment [17],
were reported only for the 2 MIU/day dose (25%). One patient in the
2 MIU/day group withdrew from treatment after 2 days of treatment
in the third cycle because of severe flu-like symptoms not responding
to symptomatic therapy (see Fig. 1).
Outside treatment cycles, only one case of nausea/vomiting was
imputed to treatment among other AEs. One patient (1 MIU/day
group) with a history of prostatic adenoma developed severe urinary
retention 10 days after the last administration and required hospital-
isation for prostatic surgery. Other events were related to ALS disease
or other pre-existing conditions.
No abnormalities were observed among the routine laboratory
parameters, except for an elevation of C - reactive protein at day 8 in
the one patient developing flu-like symptoms in the 2 MIU/day
group, and another at D57 in relation to a viral infection. As for hae-
matology parameters, no significant changes were observed except
for eosinophil counts that were significantly increased compared to
placebo at day D8 and D64 in the 2 MIU/day group (Supplementary
Table 2); changes of a lesser degree were observed at 1 MIU/day and
were significant only at D64. In the 2 MIU/day group, 3 patients pre-
sented eosinophil increases above 1¢5 £ 109/l but remained asymp-
tomatic. All counts were close to baseline values at D169 (no
significant differences between groups) and all within normal range.
The a priori defined primary pharmacodynamic outcome of an
increase in the frequency of Tregs as a percentage of CD4+ T-pants.
IL2 at 1 MIU/d (n = 12) IL2 at 2 MIU/d (n = 12)
54¢98 (10¢99) 57¢68 (12¢91)
) 54¢80 (40¢2 to 75¢4) 61¢25 (36¢5 to 76¢6)
5 (41¢7%) 3 (25%)
25¢34 (2¢53) 24¢39 (1¢71)
) 24¢90 (21¢90 to 28¢7) 24¢35 (21¢6 to 26¢7)
52¢43 (11¢02) 55¢80 (12¢86)
) 52¢20 (37¢4 to 72¢6) 58¢25 (35¢1 to 76¢0)
2¢60 (1¢33) 1¢96 (1¢44)
2¢85 (0¢9 to 4¢6) 1¢45 (0¢6 to 4¢6)
20¢70 (14¢90) 14¢18 (11¢47)
17¢45 (5¢0 to 45¢1) 11¢10 (3¢1 to 34¢0)
6 (50%) 4 (33¢3%)
6 (50%) 3 (25%)
0 (0%) 5 (41¢7%)
2 (16¢7%) 2 (16¢7%)
11 (92%) 9 (75%)
1 (8%) 3 (25%)
101¢5 (18¢1) 93¢6 (16¢3)
¢00) 101¢0 (79¢00 to 132¢00) 94¢5 (72¢00 to 118¢00)
38¢0 (4¢8) 37¢8 (5¢3)
0) 38¢0 (30¢00 to 44¢00) 39¢5 (26¢00 to 44¢00)
135.55 (76.80) 178.19 (94.84)
103.4 (46.2 - 245.5) 144.2 (109.1 - 460.0)
rophic Lateral Sclerosis Functional Rating Score  Revised.
rofilament light chain protein  electroluminescent detec-
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Table 3
Immune cell parameters at baseline (D1) and response.
Dose group Baseline D1 D8 change from D1 D64 change from D1 iAUC trough D29-D57-D85 D169 change from D1
CD8 (% CD3+) 2 MIU 25¢0 (8¢9) 3¢1 (1¢7)** 4¢3 (2¢6)** 1¢4 (1¢1) 1¢4 (1¢4)
1 MIU 24¢1 (6¢2)) 2¢0 (1¢2)* 2¢7 (1¢3)** 1¢0 (0¢6) 0¢6 (1¢4)
Placebo 26¢1 (9¢0) 0¢4 (2¢3) 0¢3 (2¢5) 0¢9 (1¢5) 1¢5 (2¢4)
Treg (% CD4+) 2 MIU 7¢6 (2¢4) 6¢2 (2¢2)**** 7¢6 (3¢9)**** 0¢4 (1¢2)*** 0¢2 (1¢0)
1 MIU 7¢6 (1¢8) 3¢9 (1¢2)**** 4¢4 (1¢5)**** 0¢1 (0¢9)** 0¢1 (0¢9)
Placebo 7¢1 (1¢5) 0¢5 (1¢3) 1¢2 (1¢2) 0¢5 (0¢3) 0¢3 (1¢4)
NK (% CD45+) 2 MIU 2¢4 (1¢0) 1¢4 (0¢9)*** 1¢2 (0¢9)*** 0¢4 (0¢5) 0¢2 (0¢5)
1 MIU 3¢2 (2¢1) 1¢1 (1¢0)** 1¢4 (0¢8)*** 0¢2 (0¢5) 0¢1 (0¢9)
Placebo 3¢6 (2¢4) 0¢2 (0¢8) 0¢1 (0¢7) 0¢2 (0¢6) 0¢6 (1¢4)
CD19 (% CD45+) 2 MIU 3¢5 (2¢0) 0¢3 (0¢9) 0¢2 (1¢1) 0¢1 (0¢8) 0¢3 (1¢2)
1 MIU 3¢3 (1¢0) 0¢3 (0¢4) 0¢2 (0¢2) 0¢1 (0¢3) 0¢3 (0¢5)
Placebo 3¢4 (1¢8) 0¢1 (0¢9) 0¢2 (0¢6) 0¢2 (0¢5) 0¢1 (0¢4)
Monocytes (% CD45+) 2 MIU 6¢7 (1¢2) 0¢6 (1¢4) 1¢4 (1¢3)** 0¢7 (1¢3) 0¢9 (1¢7)
1 MIU 5¢4 (1¢2)* 0¢5 (0¢5) 0¢04 (0¢6) 0¢1 (0¢5) 0¢1 (0¢5)
Placebo 7¢3 (2¢5) 0¢2 (1¢0) 0¢1 (1¢0) 0¢2 (0¢6) 0¢2 (0¢8)
Eosinophils (% total WBCa) 2 MIU 2¢7 (1¢8) 3¢3 (1¢5)*** 6¢8 (4¢1) *** 1¢8 (1¢0)*** 0¢4 (1¢3)
1 MIU 2¢3 (1¢8) 1¢0 (0¢8) 2¢5 (2¢2)** 0¢6 (0¢5) 0¢2 (0¢7)
Placebo 2¢3 (0¢9) 0¢6 (0¢7) 0¢4 (1¢2) 0¢2 (0¢6) 0¢6 (1¢0)
Results are expressed as relative frequency: mean (SD). a total leukocytes from haematology lab. Comparisons of each dose group to placebo group by Mann-Whitney
test: *p< 0¢05, ** p<0¢01, *** p<0¢001, **** p<0¢0001.
Table 2
Safety number of patients (frequency) presenting non-serious adverse events during treatment cycles.
Adverse events Treatment group Total (N = 36)
2 MIU (N = 12) 1 MIU (N = 12) Placebo (N = 12)
Injection site reactions 12 (100%) 11 (91¢7%) 1 (8¢3%) 24 (66¢7%)
Flu-like symptoms 3 (25¢0%) 0 0 3 (8¢3%)
Fatigue 2 (16¢7%) 1 (8¢3%) 2 (16¢7%)0 5 (13¢9%)
Gastro-intestinal signs 2 (16¢7%) 1 (8¢3%) 0 3 (8¢3%)
Rhinitis 2 (16¢7%) 0 0 2 (5¢6%)
Nasopharyngitis 1 (8¢3%) 1 (8¢3%) 0 2 (5¢6%)
Headache/Migraine 4 (33¢3%) 0 0 4 (11¢1%)
Chest pain 1 (8¢3%) 0 0 1 (2¢8%)
Cold sweat 0 1 (8¢3%) 0 1 (2¢8%)
Arthralgia 1 (8¢3%)0 0 0 1 (2¢8%)
Myalgia 0 0 1 (8¢3%) 1 (2¢8%)
Total 12 (100%) 11 (91¢7%) 3 (25¢0%) 26 (72¢2%)
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6 W. Camu et al. / EBioMedicine 00 (2020) 102844lymphocytes at D8 was dose-dependent (JT-J test, p < 0.0001) and
highly significant for both treated arms (MW-U test, p < 0¢0001; 2
MIU: mean [SD]: +6¢2% [2¢2]; 1 MIU: mean [SD]: +3¢9% [1¢2]) as com-
pared to placebo (mean [SD]: 0¢5% [1¢3]) (see Table 3, Fig. 2a and b).
Effect sizes were large for both IL-2 groups: 2 MIU ES=3¢7 (95% CI:
2¢34¢9); 1 MIU ES=3¢5 (95% CI: 2¢14¢6). Furthermore, when exam-
ining the range of change from baseline in Treg frequency, a clear dis-
tinction was observed in all IL-2 recipients (range of change: +23 to
+139%) with no overlap with the placebo group (range of change:
51 to +9%, Fig. 2a). Secondary outcomes for Tregs revealed that the
frequency and absolute count significantly and dose-dependently
(JT-J test, p < 0.0001 for both frequency and absolute count)
increased compared to baseline and placebo during subsequent treat-
ment cycles (Fig. 2ad, Table 3 and Supplementary Table 2). Further-
more, the peak during cycle 3 tended to be higher than that observed
during cycle 1, suggesting that successive treatment cycles have
residual effects that might be cumulative. This suggestion is further
supported by significantly higher iAUC trough Treg levels (measuring
the residual Treg change before beginning a new cycle) in IL-2 arms
as compared to placebo (Fig. 2e and f, Table 3 and Supplementary
Table 2). Overall, the 2 MIU arm resulted in higher Treg peaks and
trough levels than the 1 MIU arm. Ld-IL-2 also resulted in a moderate
increase in the frequency and number of NK cells for both IL-2 groups
(maximum 1¢7 fold increase in number at D64 for the 2 MIU group);
an increase in the number of CD8 T cells for both IL-2 groups (maxi-
mum 1¢4 fold increase in number at D64 for the 2 MIU group); an
increase in the number of CD4+ Teffs for both ld-IL-2 groupsPlease cite this article as: W. Camu et al., Repeated 5-day cycles of low d
2a randomised, double-blind, placebo-controlled trial, EBioMedicine (202(maximum 1¢6 fold increase in number at D64 for the 2 MIU group)
and a decrease in the frequency of monocytes in the 2 MIU group at
D64 (all data shown in Table 3 and Supplementary Table 2).
Exploratory analyses of Treg phenotype and function were per-
formed using cryopreserved PBMC focussing primarily on responses
at baseline and following 3 cycles of treatment (D1 and D64). We
observed good correlation between the frequency of Tregs defined in
blood by clinical cytometry and when sorting Tregs from cryopre-
served PBMC (R2=0¢91, p < 0¢0001). Similar to results in fresh blood,
analysis of cryopreserved PBMC revealed a significant increase in the
frequency of Tregs following 3 cycles of ld-IL-2 treatment (Supple-
mentary Fig. 3ac).
Furthermore, batched analysis on the same day of all time-points
from a single individual allowed direct comparison of CD25 expres-
sion on Tregs quantified through median fluorescence intensity (mfi)
(Fig. 3ac). Comparisons of percent change from baseline after three
cycles (D64) showed a significant dose dependent increase in CD25
expression on Tregs (JT-J test, p < 0.0001). Median increase in Tregs
CD25 mfi was 1.94 fold in the 2MIU arm and 1.84 fold in the 1MIU
arm (CD25 mfi, median [range], D1 vs D64: 2MIU 4651 [28925886]
vs 9015 [422014446], Wx-W test, p = 0¢002; 1 MIU = 4230
[33885423] vs 7778 [55649037], Wx-W test, p = 0¢001) compared
to no change in the placebo arm (4105 [29925656] vs 3867
[19235669], Wx-W test, p = 0¢83).
A smaller, but still significant increase in CD25 expression was
also observed on Teffs (CD25 mfi, median [range], D1 vs D64: 2 MIU=
426 [116897] vs 528 [122948], Wx-W test, p = 0¢02; 1 MIU= 336
ose aldesleukin in amyotrophic lateral sclerosis (IMODALS): A phase
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Fig. 2. Effect of IL-2 treatment on Treg number and frequency. Panels a to d: change in frequency (a-b) and absolute number (c-d) of Tregs throughout the study for all three arms
(open triangles, placebo; blue squares, 1 MIU of IL2; black circles, 2 MIU of IL2). a & c: data points indicate mean values, and error bars their associated SEMs. b & d: change in the
number and frequency of Tregs between baseline and the three days after the final injection of one treatment cycle (D8) or 3 treatment cycles (D64). Data points represent the per-
patient change in Treg frequency (b) and number (d). Three group comparisons by the Kruskal-Wallis H test at D8 and D64 (p < 0.0001) for panel b and d. Panels e-f: iAUC of trough
levels of Tregs during the study. Data points indicate mean values, and error bars their associated SEMs for Treg number (e) and frequency (f). Verum to placebo comparisons by the
Mann-Whitney U test: *** p < 0.001, ** p < 0.01.
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[195919] vs 263 [158881], Wx-W test, p = 0¢24; Supplementary
Fig. 3df).
Treg function was assessed by in vitro co-culture assays using
Teffs from the corresponding time point as responder cells. In cul-
tures lacking Tregs, we observed no effect of ld-IL-2 administrationPlease cite this article as: W. Camu et al., Repeated 5-day cycles of low d
2a randomised, double-blind, placebo-controlled trial, EBioMedicine (202on the proliferation of responder T cells (Supplementary Fig. 3gi).
However, we did observe an increase in suppressive function of Tregs
following 3 cycles of ld-IL-2 therapy, which reached statistical signifi-
cance for the 1 MIU dose (percent suppression, median [range], D1 vs
D64: 2 MIU = 53% [18-88] vs 76% [19-91], Wx-W test, p = 0¢06; 1
MIU = 65% [23-84] vs 80% [36-97], Wx-W test, p = 0¢001; Fig. 3d and
ose aldesleukin in amyotrophic lateral sclerosis (IMODALS): A phase
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Fig. 3. Effect of IL-2 treatment on Treg phenotype and suppressive function. Panel a to c: CD25 mfi expression on Tregs at baseline (D1) and 3 days after completion of 3 treatment
cycles (D64) in all three study groups: (a) 2 MIU, (b) 1 MIU and (c) placebo. Panels d to f: autologous suppressive function of Tregs measured by in vitro co-culture assay at baseline
(D1) and 3 days after completion of 3 treatment cycles (D64) in individuals treated with (d) 2 MIU, (e) 1 MIU and (f) placebo. Panel g: Change in suppressive function of Tregs follow-
ing 3 cycles of treatment relative to baseline levels in all three groups. Bars represent mean values, and error bars their associated SEMs. Panels h-i: Relationship between the rela-
tive change in Treg frequency (h) and Treg CD25 mfi (i) measured by mechanistic immunophenotyping cytometry (x-axis) and Treg suppressive function (Y axis) following 3 cycles
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Fig. 4. Effect of IL-2 treatment on plasma chemokine concentrations. Panels a to c: variation in plasma chemokine levels throughout the study for CCL2 (a), CCL17 (b) and CCL18 (c).
Concentrations are expressed as a percentage of baseline value for each individual and points indicate mean values, and error bars their associated SEMs. Open triangles denote indi-
viduals receiving placebo, blue squares 1 MIU and black circles 2 MIU of IL2. Three dose comparisons at D64 panels a to c, by the Kruskal-Wallis rank test: (a) p < 0.005; (b)
p < 0.0001; (c) p < 0.0028.
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placebo group (percent suppression, median [range], D1 vs D64: pla-
cebo= 73% [5395] vs 59% [32-97]; Wx-W test, p = 0¢07; Fig. 3f).
When comparing the percent change in Treg suppressive function
over the treatment period (relative to suppression at baseline), we
observed a significant difference between both groups treated with
ld-IL-2 when compared to placebo (KW-H test, p < 0.0021, 2 MIU vs
placebo, MW-U test, p = 0¢0076; 1 MIU vs placebo, MW-U test,
p = 0¢001; Fig. 3g). We also assessed the relationship between the
change in Treg suppressive function and the change in Treg fre-
quency or change in CD25 expression in response to treatment for
each individual. In both cases, we observed a highly significant corre-
lation between these measurements (Treg suppressive function vs
Treg frequency: R2=0¢42, p = 0¢0001, Treg suppressive function vs
Treg CD25 mfi: R2=0¢33, p = 0¢001 Fig. 3h-i) with individuals
who received ld-IL-2 clearly clustering away from those who
received placebo.
Plasma levels of the CCL2 chemokine were assessed in order to
evaluate the potential for a therapeutic impact of ld-IL-2 on individu-
als with ALS through change in this marker of disease activity. Fol-
lowing the third treatment cycle (D64), we observed a significant
difference between the three groups in the plasma levels of CCL2
(KW-H test, p = 0¢005, Fig. 4a), both active dose groups showing a
dose-dependent change in CCL2 levels (JT-J test, p = 0.0049), which
were significantly reduced compared to placebo with the 2 MIU dose
(MW-U test, p = 0¢005), though not reaching statistical significance
with the 1 MIU dose (MW-U test, p = 0¢06). Second, we measured
plasma levels of chemokines associated with macrophage/microglial
polarization (CCL17 and CCL18). We observed a significant difference
between treatment groups at D64 in CCL17 and CCL18 (KW-H tests,
p = 0¢0001 and 0¢0028, respectively, Fig. 4b and c), with an increase
in both treatment groups compared to placebo (MW-U tests, CCL17:
2 MIU p = 0¢0001 and 1 MIU p = 0¢0138; CCL18: 2 MIU p = 0¢0012 and
1 MIU p = 0¢0094). For all three chemokines, in both treated group
values returned to baseline by D85 (cycle 3 trough level).
These results suggest that ld-IL-2 treatment was associated with a
decrease of an inflammatory marker associated with ALS, and a con-
comitant shift of monocytes towards the M2 phenotype.
With regard to disease progression, we did not observe any signif-
icant differences among the three groups with regards to time related
changes in the ALSFRS-R score (KW-H test, p = 0¢12), slow vital capac-
ity (KW-H test, p = 0¢59), or plasma NFL-MSD levels (KW-H test,of treatment (values at D64 vs D1). Open triangles denote individuals receiving placebo, blue
ns: p > 0.05 by the Wilcoxon match paired sign rank test (a to f) and by the Mann-Whitney t
Please cite this article as: W. Camu et al., Repeated 5-day cycles of low d
2a randomised, double-blind, placebo-controlled trial, EBioMedicine (202p = 0¢84; supplementary Fig. 4). For NFL, re-analysis of the plasma
samples using the Simoa approach provided similar results (KW-H
test, p = 0¢30). However, in the overall population, none of these
parameters showed statistically significant changes over the treat-
ment period  ALSFRS-R (points/month) mean slope [95% CI]= 0¢8
[2¢4, +0¢8]; SVC (percent predicted) mean change at D85 from D1
[95% CI]= 2¢2 [23¢4, +19¢0]; NFL-MSD D85 change from D1, (pg/
ml) mean change [95% CI] = + 0¢63 [62¢5, + 63¢7]; NFL-SIMOA D85
change from D1, (pg/ml) mean change [95% CI] = 1¢64 [26¢25,
+22¢97]  demonstrating that these parameters were poorly sensi-
tive to change over the relatively short treatment period.
4. Discussion
First, our results show that IL-2 at two low doses was clinically
well tolerated in ALS subjects over three cycles, and no further safety
issues were detected following treatment withdrawal. In keeping
with previous reports [16], our findings show that ALS patients, who
are particularly vulnerable to treatment toxicity, can withstand
repeated cycles of treatment with ld-IL-2. The safety of ld-IL-2 is fur-
ther supported by the lack of significant deterioration in ALSFRS-R or
SVC over the treatment period across all groups, and within groups,
including placebo. The lack of any detectable functional change may
be related to the relative insensitivity to change of these clinical out-
come measures over the short treatment period, but is nonetheless
reassuring in terms of safety.
Second, we observed a significant, dose dependent increase in
both the absolute number and relative frequency of Tregs in both the
2 MIU and 1 MIU groups. Comparing these results to those obtained
in a double-blind randomised clinical trial in individuals with Type 1
Diabetes [17], we observed a similar magnitude of Treg response to
ld-IL-2, with a ~1¢5-fold increase in the Treg percentage of CD4+ cells
following 5 days of treatment at 1 MIU.
Of note, all individuals in both groups on active treatment showed
an increase in Treg number and frequency. Thus, although it has been
suggested that Tregs from ALS patients may have impaired endoge-
nous responsiveness to IL-2 [22], potentially making them unrespon-
sive to ld-IL-2 treatment, in this cohort of ALS patients we observed
no evidence of intrinsic impairment in Treg responsiveness to
ld-IL-2.
Third, we have shown that the increase in Treg response was sus-
tained over 4 weeks following a 5-day treatment cycle. This issquares 1 MIU and black circles 2 MIU of IL2. **** p < 0.0001, *** p < 0.001, ** p < 0.01,
est (g).
ose aldesleukin in amyotrophic lateral sclerosis (IMODALS): A phase
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increase in Treg levels, and therefore potentially a continuous life-
long treatment with ld-IL-2. We selected our treatment schedule
based on the study in type 1 diabetes [17], and the present study con-
firms a significant expansion in Treg number and frequency at trough
levels (i.e. before the start of each treatment cycle) and also that this
expansion increases with repeated cycles. However, it remains to be
verified whether our treatment schedule is the most effective for con-
trolling neuro-inflammation in ALS, or whether different treatment
schedules (e.g., more frequent administration of ld-IL-2) will be more
therapeutically useful.
Taken together, our findings suggest that in this ALS cohort there
was no loss of sensitivity to ld-IL-2 with repeated administration.
Consistent with this and in agreement with other reports [16], we
observed that ld-IL-2 leads to a preferential increase in expression of
CD25 on Tregs. This may increase sensitivity of Treg cells to both
administered and endogenous IL-2, thus potentially enhancing and
sustaining any treatment effect.
In order to understand the relevance of the change in Treg num-
ber to any treatment effect, we assessed Treg function before and
after ld-IL-2 administration. We used an autologous co-culture assay
to measure the ability of FACS-isolated Tregs to suppress the prolifer-
ation of CD4+ effector T cells. Our results demonstrate that, overall,
treatment with ld-IL-2 results in both an increase in Treg frequency
and in Treg suppressive function. This improvement in Treg function
is highly significant in the 1 MIU arm, with all individuals showing an
increase in function, while in the 2 MIU group only a trend toward
significance was observed, due to increased variation in response
between individuals. This improvement of Treg function following
ld-IL-2 treatment is consistent with previous observations in ALS that
the suppressive function of Tregs among individuals with ALS could
be improved by ex vivo expansion driven by recombinant IL-2 [22].
The dual efficacy of ld-IL-2 is illustrated by the highly significant cor-
relation between increased Treg frequency and function, though we
also observed individual variation in treatment response with some
treated individuals showing a more significant change in either Treg
frequency or Treg function and others showing an increase in both.
Conversely, individuals in the placebo group tended to lose either
Treg frequency or function during the same timeframe.
With regard to ld-IL-2 effects on blood markers of ALS disease
activity, we found a significant and dose-dependent reduction in the
plasma concentration of CCL2. CCL2 is a small chemokine belonging
to the CC subfamily which signals through the CC chemokine
receptor 2 (CCR2) and drives circulating leucocytes towards sites of
neuroinflammation [23]. CCL2 knockout mice have reduced infiltra-
tion of circulating leucocytes at sites of neuroinflammation and resis-
tance to disease in models of autoimmunity and inflammation [23],
suggesting this pathway plays a role in driving pathogenesis. Ele-
vated CCL2 expression levels have been observed in neural tissue
from individuals with ALS and are associated with infiltration and
activation of macrophages and microglia. CCL2 levels in biological flu-
ids are also elevated in individuals with ALS and have been shown to
correlate with disease score [24] and survival [5], indicating that
CCL2 is a useful biomarker of disease activity.
Mechanisms underlying the polarisation of myeloid cell activation
states have been proposed to harbour significant potential for inter-
vening in the progression of neurodegenerative diseases, including
ALS [25]. In experimental ALS models, an M1/inflammatory micro-
glial phenotype characterizes end-stage disease phases and exerts
neurotoxic activity with detrimental outcomes, while a shift to an
M2/immunoregulatory microglial phenotype has been shown to pro-
tect motor neurons [26]. Monocytes also show polarised activation,
with distinct chemokine expression profiles recognized as suitable
markers for defining their M1 or M2 profiles [27]. In experimental
ALS models, inflammatory monocytes are recruited to the spinal cord
and contribute to disease progression by increasing neuronal lossPlease cite this article as: W. Camu et al., Repeated 5-day cycles of low d
2a randomised, double-blind, placebo-controlled trial, EBioMedicine (202and reducing lifespan [28]. Interestingly, ld-IL-2 treatment was asso-
ciated with a significant increase of plasma levels of CCL17 and
CCL18, in keeping with a change in macrophage/microglial polarisa-
tion towards an immunoregulatory/M2-like phenotype [29]. To our
knowledge, there is no information on CCL17 in blood in ALS, while
CCL18 has been investigated, but no significant association with dis-
ease progression was observed [30]. It will be important in future
ALS studies to investigate these and other biomarkers of microglial
polarisation in CSF. Overall, the changes in inflammatory biomarkers
of macrophage activation and polarisation are consistent with a role
of ld-IL-2 in controlling cytopathic microglial activation associated
with ALS progression.
Tregs are known to influence macrophage activation and polarisa-
tion, primarily towards an M2-like phenotype [31], raising the possi-
bility that these changes are a direct result of the increased number
or functional capacity of Tregs induced by ld-IL-2. However, cells of
the monocyte-macrophage lineage do express functional IL-2 recep-
tors, and their expression of CD25 (IL2RA) is increased under inflam-
matory conditions [32], in keeping with the notion that macrophage/
microglial polarisation may also occur as a direct result of ld-IL-2 act-
ing directly on these cells.
Finally, we did not observe across groups any significant differ-
ence in changes in plasma NFL concentrations in response to treat-
ment. Although there was an over 20% increase in the mean of NFL
levels in the placebo group consistent with the disease progression
over time, this difference was not statistically different from zero due
to a large variance in this group. In contrast, no increase was
observed in the two ld-IL-2 treated groups. Based on published data
[19], we estimated that it should be possible to detect a treatment
effect with relatively few patients per group, but in the context of
this randomised (and strictly blinded) study, post-hoc power analysis
suggests that this is a large underestimate, as supported by recent
reports [33]. In the light of these findings it is possible that analyses
of neurofilament proteins in the CSF will be more informative [34].
Altogether, considering the dose-dependency of responses over
Treg expansion and function and of inflammatory markers CCL2,
CCL17 and CCL18, the selection of the 2 MIU IL-2 dose seems more
appropriate for further clinical development. However, the 1MIU
proved better tolerated though still significantly effective compared
to placebo. It is likely that a flexible dose approach in further clinical
development should be considered.
The main limitation of this study is that the results were
obtained on a small sample of a highly selected population of slowly
progressing patients over a short period of treatment. Although this
design minimises informative censoring due to death which ham-
pers analysis of repeated measures in ALS studies [35], it does not
allow us to generalise our findings to the overall ALS population,
nor does it provide the power to detect even large changes in clini-
cal parameters. The demonstration in an ALS population that ld-IL-2
is engaging the Treg target was a necessary step towards the next
level demonstrating ld-IL-20s potential clinical efficacy in slowing
down the rate of disease progression. In a recent experiment using
the SOD1 mouse ALS model [36], it was shown that in vivo Treg
expansion using an IL-2/IL-2 antibody complex was associated with
a significant increase in survival. Nonetheless, preclinical ALS mod-
els have unfortunately proved inadequate predicting clinical out-
comes in drug development, and in the case of ld-Il-2, are unlikely
to help defining how much Treg amplification is required to achieve
clinical benefit.
In conclusion, this study shows that ld-IL-2 is safe over 3 monthly
cycles in people with ALS. In addition, we provide clear evidence for
in vivo amplification of Treg numbers, frequency and suppressive
function with ld-IL-2. Importantly, in the light of the previous find-
ings of raised CCL2 in plasma and CSF of ALS patients, our observation
that plasma CCL2 is decreased in a dose-related fashion to ld-IL-2
treatment supports the notion that this therapeutic approach mayose aldesleukin in amyotrophic lateral sclerosis (IMODALS): A phase
0), https://doi.org/10.1016/j.ebiom.2020.102844
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W. Camu et al. / EBioMedicine 00 (2020) 102844 11translate into an effective therapy. A phase 2b/3 study based on these
observations is ongoing (www.mirocals.eu; ClinicalTrials.gov
NCT03039673), which may confirm the usefulness of these bio-
markers as early surrogate outcomes for clinical efficacy.
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